Evidence map›Paper›PMID 31489028›Full record

ReviewPakistan journal of medical sciences

MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis.

Juan Qu, Jizhi Yang, Ming Chen, Lihong Cui, Tianxi Wang, Wei Gao, Jingjing Tian, Rongna Wei

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Biomarkers for hepatocellular carcinoma based on body fluids and feces.World journal of gastrointestinal oncology · 2021
    Review
  17. Review
  18. Dairy consumption and hepatocellular carcinoma risk.Annals of translational medicine · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Juan QuJuan Qu, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Jizhi YangJizhi Yang, Department of Traditional Chinese Medicine, Chentangzhuang Hospital, Hexi District, Tianjin 300222, China.
Ming ChenMing Chen, Department of Hepatopathy and Hepatic Oncology, Tianjin Nankai Hospital, Tianjin 300100, China.
Lihong CuiLihong Cui, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Tianxi WangTianxi Wang, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Wei GaoWei Gao, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Jingjing TianJingjing Tian, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Rongna WeiRongna Wei, Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, China.
Tianjin Nankai Hospital · CNYang Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNA-21 (miR-21) is one of the oncogenic miRNAs which may be a potential diagnostic biomarker for hepatocellular carcinoma (HCC).

methodsWe systematically searched Medline, Embase, the Cochrane Library, ISI Web of Knowledge, Scopus from inception to August 15, 2018, and reference lists of identified primary studies. Two independent investigators extracted patient and study characteristics. The sensitivity and specificity of microRNA-21 for HCC detection and were analyzed with a random effect model. The area under summary receiver operating characteristic curve (AUC) was used to estimate overall test performance.

resultsA total of 515 HCC patients, and 338 healthy or chronic hepatitis controls from six published studies were enrolled in this meta-analysis. All articles were published in English with moderate-to-high quality. The overall pooled sensitivity and specificity were 85.2% (73.3% to 88.4%) and 79.2% (68.4% to 87.0%), respectively. The AUC area was 0.89 (95% CI: 0.85-0.91). The studies had moderate heterogeneity (I2=70.11%). None of the subgroups investigated-ethnicity, controls, sample source-could account for the heterogeneity.

conclusionMiR-21 is a helpful biomarker for early diagnosis of HCC. Nevertheless, the results of the test must be interpreted carefully in the context of medical history, erological tests and imaging examinations for HCC surveillance.

Indexed as

BiomarkerEarly diagnosisHepatocellular carcinomamicroRNAs

Identifiers

PMID31489028
PMCPMC6717466
OpenAlexW2968702228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.